OrthocellOCC 
2.25%24h
Orthocell (OCC) Stock Overview
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental procedure; and Remplir, a collagen scaffold used in peripheral nerve repair. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
OCC Stock Information
Orthocell (OCC) Price Chart
Orthocell Overview: Key Details and Summary
Stock data | 2023 | Change |
|---|---|---|
| Price | $0.3078234514112521 | N/A |
| Market Cap | $60.71M | N/A |
| Shares Outstanding | 197.21M | 1.31% |
| Employees | 0 | N/A |
| Shareholder Equity | 6.15M | -37.92% |
Valuation | 2023 | Change |
|---|---|---|
| P/E Ratio | -9.62 | N/A |
| P/S Ratio | 21.15 | N/A |
| P/B Ratio | 9.87 | N/A |
Growth | 2023 | Change |
|---|---|---|
| Return on Equity | -0.6875 | N/A |
Earnings | 2023 | Change |
|---|---|---|
| Revenue | $2.87M | N/A |
| Earnings | -$4.23M | N/A |
| EPS | -0.032 | N/A |
| Earnings Yield | -0.104 | N/A |
| Gross Margin | 0.7582 | N/A |
| Operating Margin | -2.57 | N/A |
| Net income margin | -1.47 | N/A |
Financial Strength | 2023 | Change |
|---|---|---|
| Total Assets | $20.03M | N/A |
| Total Debt | $380.42K | N/A |
| Cash on Hand | $16.79M | N/A |
| Debt to Equity | $2.58 | 34.98% |
| Cash to Debt | $44.14 | 103.26% |
| Current Ratio | $5.93 | 14.65% |
